Recombinant Human EGF Market, by Product Type (Heparin Binding-EGF, Transforming Growth Factor-a, Epigen, Neuregulins, Amphiregulin, Betacellulin, and Others), by Purity (98% SDS-PAGE, 95%-98% SDS-PAGE, and <95% SDS-PAGE), by Carrier Type (Carrier Protein

Recombinant Human EGF Market, by Product Type (Heparin Binding-EGF, Transforming Growth Factor-α, Epigen, Neuregulins, Amphiregulin, Betacellulin, and Others), by Purity (98% SDS-PAGE, 95%-98% SDS-PAGE, and <95% SDS-PAGE), by Carrier Type (Carrier Protein and Carrier Free), by Formulation (Lyophilized Powder, Liquid, and Others), by Application (Wound Healing, Gastrointestinal Ulceration, Brain Tumor Therapy, and Others)and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Recombinant Human EGF (Epidermal Growth Factor) is a peptide that binds to the membrane receptor called EGF receptor in humans to promote cell proliferation and cell differentiation. EGF acts by initiating number of cell signaling cascade pathways such as activating genes for cell proliferation, cell differentiation, protein synthesis, and improving efficiency of DNA topoisomerase. Traditionally, EGF was isolated from animal urine but with recent advances in biotechnology, the production and extraction of recombinant EGF have become possible in a lab setting. Recombinant EGF can be produced using various biological systems such as Escherichia coli, tobacco, rice, yeast, and others. EGF can be used for several applications in the field of medicine, research, cell culture, cosmetology, and others. EGF exhibits medically important properties such as initiation of growth and division in cells that can be exploited for clinical application of wound healing as well as for the treatment of ulcers. For instance, according to an article published by the American Institute of Physics in June 2021, high levels of recombinant human EGF (rhEGF) were obtained by co-expression of human EGF (hEGF) in Escherichia coli with Bacillus cereus phospholipase C. This rhEGF can then be used for the treatment of diabetic foot ulcers along with other wound treatments.

Market Dynamics

Market players are conducting clinical trials for analyzing the potential uses of human EGF in healthcare sector, this could contribute to the growth of the market over the forecast period. For instance, a clinical trial study was initiated in July 2017 by Hallym University Kangnam Sacred Heart Hospital, Korea, for determining the effectiveness of recombinant human EGF ointment in healing lesions caused by laser treatment for solar lentigines. The study was completed in December 2018 and the results were published by PubMed in February 2021. Results showed that the use of recombinant human EGF ointment was safe and efficient for healing lesions.

Market players are involved in acquisitions of other companies in order to enhance distribution. For instance, in 2018, FUJIFILM, a Japanese multinational conglomerate, acquired Irvine Scientific Sales Company, Inc., a cell media specialist, to expand its range of cell culture media products including recombinant human EGF. This is expected to drive the growth of the recombinant human EGF market.

Key features of the study:
This report provides an in-depth analysis of global recombinant human EGF market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global recombinant human EGF market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Thermo Fisher Scientific, FUJIFILM Irvine Scientific, Inc., ScienCell Research Laboratories, R&D Systems, Abcam PLC, Cell Sciences, Inc., Eurofins DiscoverX, PeproTech, Inc., RayBiotech, Inc., Prospec-Tany TechnoGene Ltd., Miltenyi Biotec, Tonbo Biosciences, BioLegend, Inc., EnQuire BioReagents, STEMCELL Technologies Inc., Cell Guidance Systems Ltd., Creative BioMart, Sino Biological Inc., and BioVision, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global recombinant human EGF market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the recombinant human EGF market
Detailed Segmentation:
Global Recombinant Human EGF Market, By Product Type:
Heparin Binding-EGF
Transforming Growth Factor-α
Epigen
Neuregulins
Amphiregulin
Betacellulin
Others
Global Recombinant Human EGF Market, By Purity:
98% SDS-PAGE
95%-98% SDS-PAGE
<95% SDS-PAGE
Global Recombinant Human EGF Market, By Carrier Type:
Carrier Protein
Carrier Free
Global Recombinant Human EGF Market, By Formulation:
Lyophilized Powder
Liquid
Others
Global Recombinant Human EGF Market, By Application:
Wound Healing
Gastrointestinal Ulceration
Brain Tumor Therapy
Others
Global Recombinant Human EGF Market, By Region:
North America
By Product Type:
Heparin Binding-EGF
Transforming Growth Factor-α
Epigen
Neuregulins
Amphiregulin
Betacellulin
Others
By Purity:
98% SDS-PAGE
95%-98% SDS-PAGE
<95% SDS-PAGE
By Carrier Type:
Carrier Protein
Carrier Free
By Formulation:
Lyophilised Powder
Liquid
Others
By Application:
Wound Healing
Gastrointestinal Ulceration
Brain Tumor Therapy
Others
By Country:
U.S.
Canada
Latin America
By Product Type:
Heparin Binding-EGF
Transforming Growth Factor-α
Epigen
Neuregulins
Amphiregulin
Betacellulin
Others
By Purity:
98% SDS-PAGE
95%-98% SDS-PAGE
<95% SDS-PAGE
By Carrier Type:
Carrier Protein
Carrier Free
By Formulation:
Lyophilised Powder
Liquid
Others
By Application:
Wound Healing
Gastrointestinal Ulceration
Brain Tumor Therapy
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type:
Heparin Binding-EGF
Transforming Growth Factor-α
Epigen
Neuregulins
Amphiregulin
Betacellulin
Others
By Purity:
98% SDS-PAGE
95%-98% SDS-PAGE
<95% SDS-PAGE
By Carrier Type:
Carrier Protein
Carrier Free
By Formulation:
Lyophilised Powder
Liquid
Others
By Application:
Wound Healing
Gastrointestinal Ulceration
Brain Tumor Therapy
Others
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Product Type:
Heparin Binding-EGF
Transforming Growth Factor-α
Epigen
Neuregulins
Amphiregulin
Betacellulin
Others
By Purity:
98% SDS-PAGE
95%-98% SDS-PAGE
<95% SDS-PAGE
By Carrier Type:
Carrier Protein
Carrier Free
By Formulation:
Lyophilised Powder
Liquid
Others
By Application:
Wound Healing
Gastrointestinal Ulceration
Brain Tumor Therapy
Others
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific

Middle East
By Product Type:
Heparin Binding-EGF
Transforming Growth Factor-α
Epigen
Neuregulins
Amphiregulin
Betacellulin
Others
By Purity:
98% SDS-PAGE
95%-98% SDS-PAGE
<95% SDS-PAGE
By Carrier Type:
Carrier Protein
Carrier Free
By Formulation:
Lyophilised Powder
Liquid
Others
By Application:
Wound Healing
Gastrointestinal Ulceration
Brain Tumor Therapy
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Product Type:
Heparin Binding-EGF
Transforming Growth Factor-α
Epigen
Neuregulins
Amphiregulin
Betacellulin
Others
By Purity:
98% SDS-PAGE
95%-98% SDS-PAGE
<95% SDS-PAGE
By Carrier Type:
Carrier Protein
Carrier Free
By Formulation:
Lyophilised Powder
Liquid
Others
By Application:
Wound Healing
Gastrointestinal Ulceration
Brain Tumor Therapy
Others
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Thermo Fisher Scientific*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
FUJIFILM Irvine Scientific, Inc.
ScienCell Research Laboratories
R&D Systems
Abcam PLC
Cell Sciences, Inc.
Eurofins DiscoverX
PeproTech, Inc.
RayBiotech, Inc.
Prospec-Tany TechnoGene Ltd
Miltenyi Biotec
Tonbo Biosciences
BioLegend, Inc.
EnQuire BioReagents
STEMCELL Technologies Inc.
Cell Guidance Systems Ltd.
Creative BioMart
Sino Biological Inc.
BioVision, Inc.
“*” marked represents similar segmentation in other categories in the respective section.